Tim Bartels, AD/PD 2022: α-Synuclein as a Novel Biomarker in Parkinson’s Disease
α-Synuclein conformations are discussed as potentially novel blood biomarkers in Parkinson’s disease (PD). Dr Tim Bartels (UK Dementia Research Institute, University College London, London, UK) joins touchNEUROLOGY to discuss an ultrasensitive assay with antibodies directed against α-Synuclein multimers in blood, which may help to detect slight and early changes in this possible novel PD biomarker.
The abstract entitled: ‘α-Synuclein Conformations as Novel Biomarkers in Blood of PD Patients‘ was presented at the International Conference of Alzheimer’s and Parkinson’s diseases and related neurological disorders (AD/PD), 13-15 October 2021.
Questions:
- What is the role of the α-Synuclein protein in Parkinson’s disease (PD)? (0:19)
- What is known about different conformations of the α-Synuclein protein in PD? (1:03)
- What was the objective, methodology and findings of the current study? (2:09)
- What is the potential clinical significance of this novel biomarker, and what future studies are planned? (6:45)
Disclosures: Tim Bartels has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of AD/PD 2022.
